Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02662764 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg
A Phase 3 study of Moderate-to-severe Acute Pain, sponsored by Talphera.
- Completed
- Registry status
- Phase 3
- Development phase
- 320
- Enrollment target
- 11
- Study locations
NCT02662764: Completed Phase 3 study of Moderate-to-severe Acute Pain, sponsored by Talphera.
NCT02662764 is a Phase 3 study of Moderate-to-severe Acute Pain that has completed, run by Talphera. The registered enrollment target is 320 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (59% lower). The trial reports 11 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02662764, a Phase 3 study of Moderate-to-severe Acute Pain, has completed, sponsored by Talphera.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 320 participants
- Enrollment target
- 11
- Study locations
Study Summary
Study to evaluate the overall performance of the Zalviso System™ (sufentanil sublingual tablet system) 15 mcg
Conditions Studied
Interventions
- DRUG Zalviso™ 15 mcg
Study Locations (11)
Florida
- Gulfcoast Research Associates - Sarasota
- G&G Research - Vero Beach
- Orthopedic Center of Vero Beach - Vero Beach
- Visions Clinical Research - Wellington
Alabama
- Eliza Coffee Memorial Hospital - Florence
- Shoals Medical Trials - Sheffield
Texas
- Westside Surgical Hospital - Houston
- Hermann Drive Surgical Hospital - Houston
Arizona
- Arizona Research Center - Phoenix
Georgia
- Southeastern Center for Clinical Trials - Decatur
Utah
- Jean Brown Research - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2016-09-28 |
| Est. Completion | 2017-05-05 |
| Phase | Phase 3 |
What the finished NCT02662764 record still lists
NCT02662764 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Moderate-to-severe Acute Pain appearing as the primary indexed condition, and to 1 intervention - of which Zalviso™ 15 mcg is the first listed.
NCT02662764 lists 11 locations in 6 states (Florida, Alabama, Texas).
Frequently Asked Questions
What is clinical trial NCT02662764 about?
NCT02662764 is a clinical study titled "Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg". Study to evaluate the overall performance of the Zalviso System™ (sufentanil sublingual tablet system) 15 mcg
What is the current status of trial NCT02662764?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 320 participants. The study started on 2016-09-28. Estimated completion is 2017-05-05.
What conditions does trial NCT02662764 study?
This clinical trial studies the following conditions: Moderate-to-severe Acute Pain.
What interventions are being tested in trial NCT02662764?
The interventions under investigation include: Zalviso™ 15 mcg (DRUG).
Who is sponsoring clinical trial NCT02662764?
This trial is sponsored by Talphera, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02662764 being conducted?
This trial has 11 study locations across Alabama, Arizona, Florida, Georgia, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02662764's enrollment target sits among peer trials
320 1082nd of 2000 higher than 914 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI